Your email has been successfully added to our mailing list.

×
0.00133620369683028 0.00185583846781976 -0.00386014401306518 -0.00274144458466342 -0.00630985079058714 0.00274664093237328 0.0109123301907802 0.0160344443619627
Stock impact report

Seattle Genetics Announces U.S. FDA Approval of TUKYSA™ (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer

Seagen Inc. (SGEN) 
Last seagen inc. earnings: 4/30 04:02 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.seattlegenetics.com
Company Research Source: Business Wire
-Approved for Patients with HER2-Positive Metastatic Breast Cancer Who Have Received One or More Prior Anti-HER2 Therapies in the Metastatic Setting--First HER-2 Tyrosine Kinase Inhibitor in Combination to Improve Overall and Progression-Free Survival in Patients with Metastatic HER2-Positive Breast Cancer With or Without Brain Metastases--Application Approved Four Months Prior to Action Date Under FDA’s Real-Time Oncology Review (RTOR)--Investor Conference Call Today at 1:00 p.m. Pacific Time (PT); 4:00 p.m. Eastern Time (ET)- BOTHELL, Wash.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today announced the U.S. Food and Drug Administration (FDA) granted approval to TUKYSA™ (tucatinib) tablets in combination with trastuzumab and capecitabine for adult patients with advanced unresectable (cannot be surgically removed) or metastatic HER2-positive breast cancer, including patients with brain metastases (disease that has spread to the brain), who have received one or more prio Show less Read more
Impact Snapshot
Event Time:
SGEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for SGEN alerts
Opt-in for
SGEN alerts

from News Quantified
Opt-in for
SGEN alerts

from News Quantified